JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01877 JUNSHI BIO

Trading 07-29 10:15:04

18.410

-0.110

-0.59%

High18.790	Low18.170	Vol376.20K
Open18.550	D1 Closing18.520	Amplitude3.35%
Mkt Cap18.91B	Tradable Cap4.79B	Total Shares1.03B
T/O6.92M	T/O Rate0.14%	Tradable Shares260.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"JUNSHI BIO","latestPrice":18.41,"timestamp":1785291288597,"preClose":18.52,"halted":0,"volume":376200,"delay":0,"changeRate":-0.005939524838012928,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"Trading","change":-0.11,"latestTime":"07-29 10:15:04","open":18.55,"high":18.79,"low":18.17,"amount":6919120,"amplitude":0.033477,"askPrice":18.45,"askSize":200,"bidPrice":18.41,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.691,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1785297600000},"marketStatusCode":2,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":18.52,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":1.241076,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"Shanghai Junshi Biosciences Co.,Ltd.","latestPrice":36.12,"timestamp":1785291302000,"preClose":35.72,"halted":0,"volume":4115400,"delay":0,"premium":"-55.97"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2653859718","title":"Junshi Biosciences Completes 300 Million Yuan Second Tranche Bond Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2653859718","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653859718?lang=en_us&edition=fundamental","pubTime":"2026-07-23 10:30","pubTimestamp":1784773839,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  completed the issuance of its 2026 second tranche of technology innovation bonds and received the proceeds on Tuesday, according to a Wednesday Hong Kong bourse filing.The company issued the three-year bonds with a total principal amount of 300 million yuan at an interest rate of 2.59%.The bonds will mature on July 22, 2029, the filing showed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TMF","US12M.BOND","BK1583","US2Y.BOND","US10Y.BOND","BK1515","US6M.BOND","TLT","US7Y.BOND","US3Y.BOND","TLTW","01877","688180","BK1161","US5Y.BOND","US30Y.BOND","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653973919","title":"Shanghai Junshi's Toripalimab Supplemental Application Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2653973919","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653973919?lang=en_us&edition=fundamental","pubTime":"2026-07-22 13:38","pubTimestamp":1784698701,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences'  supplemental application to expand the indication of toripalimab  for resectable non-small cell lung cancer has been accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The application seeks to expand the approved patient population to include adult patients with resectable stage II-III NSCLC, from the current stage IIIA-IIIB indication, with toripalimab used in combination with platinum-based chemotherapy as perioperative treatment, followed by toripalimab monotherapy as adjuvant treatment.Shanghai-listed shares of the biopharmaceutical company were up nearly 2%, while Hong Kong-listed shares were down nearly 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01877","BK1583","BK1515","688180","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653201259","title":"Shanghai Junshi Biosciences Gets NMPA Acceptance Notice of Supplemental Application for Toripalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2653201259","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653201259?lang=en_us&edition=fundamental","pubTime":"2026-07-22 00:22","pubTimestamp":1784650942,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For ToripalimabJuly 21 (Reuters)-Shanghai Junshi Biosciences Co Ltd688180.SS:ACCEPTANCE OF SUPPLEMENTAL APPLIC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N0AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180","01877","BK1515","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653420380","title":"Shanghai Junshi Biosciences - Acceptance of Supplemental Application for Toripalimab in Combination with Chemotherapy as Perioperative Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653420380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653420380?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:40","pubTimestamp":1784641221,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N0AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1161","01877","BK0239","BK1515","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653038062","title":"Shanghai Junshi Biosciences - Acceptance Notice Issued by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2653038062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653038062?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:40","pubTimestamp":1784641221,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N0AI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01877","BK1515","BK0239","BK1583","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119004474","title":"Zhongou Fund's Ge Lan Q2 Report Revealed: Junshi Bio Enters Top Holdings, Kelun Pharma Sees Major Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=1119004474","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119004474?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:13","pubTimestamp":1784639606,"startTime":"0","endTime":"0","summary":"During the second quarter of 2026, two healthcare-focused funds managed by Zhongou Fund's Investment Director, Ge Lan, outperformed their benchmarks against the market trend.In her recently disclosed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","002422","01877","LU1064130708.USD","BK0239","LU1979443071.USD","LU2148510915.USD","BK1515","LU1934453819.USD","BK0060","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185053835","title":"HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185053835","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185053835?lang=en_us&edition=fundamental","pubTime":"2026-07-20 11:36","pubTimestamp":1784518575,"startTime":"0","endTime":"0","summary":"Monday, July 20, Hong Kong biomedical shares staged a broad rally. $REMEGEN(09995)$, $WUXI XDC(02268)$ and $KEYMED BIO-B(02162)$ climbed more than 8%, while $JUNSHI BIO(01877)$ gained over 7% and $AKESO(09926)$ advanced above 6%. $WUXI BIO(02269)$ edged up nearly 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02162","02268","09926","02269","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179369678","title":"JUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1179369678","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179369678?lang=en_us&edition=fundamental","pubTime":"2026-07-10 10:36","pubTimestamp":1783650988,"startTime":"0","endTime":"0","summary":"The stock price of JUNSHI BIO (01877) has climbed more than 5%, with a gain of 5.44% to HK$19.53 at the time of reporting, on a trading volume of approximately HK$44.26 million.The catalyst for the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","BK4588","01877","BK1583","VXUS","BK1161","BK4585","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187733817","title":"JUNSHI BIO Seeks Shareholders’ Nod for 10% H-Share Buyback Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1187733817","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187733817?lang=en_us&edition=fundamental","pubTime":"2026-07-08 22:24","pubTimestamp":1783520668,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (JUNSHI BIO) has issued a circular dated 8 July 2026 convening a First Extraordinary General Meeting (EGM) on 27 July 2026 in Shanghai. The sole special...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191400913","title":"Junshi Biosciences to Seek H-Share Repurchase Mandate at 27 July 2026 EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1191400913","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191400913?lang=en_us&edition=fundamental","pubTime":"2026-07-08 22:24","pubTimestamp":1783520665,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) has issued a notice for its 2026 first extraordinary general meeting (EGM), scheduled for 27 July 2026 at 2:50 p.m. on the 15th Floor,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156374670","title":"Junshi Biosciences Sets 22–27 July 2026 H-Share Register Closure to Confirm First EGM Entitlements","url":"https://stock-news.laohu8.com/highlight/detail?id=1156374670","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156374670?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:05","pubTimestamp":1783515917,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. has scheduled a suspension of H-share transfers from Wednesday, 22 July 2026 to Monday, 27 July 2026, both dates inclusive. The temporary closure will allow the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649690608","title":"Possible Turnaround For Shanghai Junshi Biosciences Insiders, Still Down CN¥4.6m","url":"https://stock-news.laohu8.com/highlight/detail?id=2649690608","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649690608?lang=en_us&edition=fundamental","pubTime":"2026-07-05 09:44","pubTimestamp":1783215847,"startTime":"0","endTime":"0","summary":"Insiders who bought CN¥21.4m worth of Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) stock in the last year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/possible-turnaround-for-shanghai-junshi-biosciences-insiders","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/possible-turnaround-for-shanghai-junshi-biosciences-insiders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1515","01877","CN","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166669760","title":"Junshi Bio June 2026 Monthly Return: Share Capital Unchanged, 37.91 Million Options Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1166669760","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166669760?lang=en_us&edition=fundamental","pubTime":"2026-07-03 16:43","pubTimestamp":1783068201,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) filed its Monthly Return for the period ended 30 June 2026, confirming that no changes occurred in authorised or issued share capital during the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648288575","title":"Shanghai Junshi Biosciences HK Shares Hit 4-week Peak on Fosun's Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2648288575","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648288575?lang=en_us&edition=fundamental","pubTime":"2026-07-02 11:27","pubTimestamp":1782962830,"startTime":"0","endTime":"0","summary":"BUZZ-Shanghai Junshi Biosciences HK shares hit 4-week peak on Fosun's licensing deal** Hong Kong shares of Shanghai Junshi Biosciences1877.HKjump 14.5% to HK$19.06, their highest level since June 2** ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nL1N43402G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK1515","BK0239","600196","BK0028","BK0012","688180","01877","02196","BK1583","BK1593","BK0188","00656","BK0096","BK0196","BK1161","BK1230","BK0175","BK0183","BK1191","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108387678","title":"JUNSHI BIO Shares Surge Over 11% on Licensing Agreement for Novel Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1108387678","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108387678?lang=en_us&edition=fundamental","pubTime":"2026-07-02 09:30","pubTimestamp":1782955831,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (HKG: 01877) shares opened sharply higher, gaining more than 11%. At the time of writing, the stock is up 11.11% to HK$18.5, with a turnover of HK$1.6724 million. The significant move...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1515","BK1161","01877","VXUS","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102844707","title":"Junshi Biosciences licenses anti-IL-17A antibody “Roconkibart” to Fosun Wanbang in RMB1.34 billion deal for Greater China","url":"https://stock-news.laohu8.com/highlight/detail?id=1102844707","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102844707?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:43","pubTimestamp":1782906226,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”) has signed an exclusive licensing agreement with Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., a wholly owned subsidiary of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648510555","title":"Shanghai Junshi Biosciences - Will Grant Fosun Wanbang Right to Develop, Others, Roconkibart (\"js005\") in Greater China Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2648510555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648510555?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:37","pubTimestamp":1782905846,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nFWN43302B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01877","BK1515","BK1161","BK0239","BK1583","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647327725","title":"Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2647327725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647327725?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:33","pubTimestamp":1782725580,"startTime":"0","endTime":"0","summary":"Chinese biopharma stocks rallied on Monday, as investors moved away from artificial-intelligence stocks amid concerns over overstretched valuations.Shares of BeOne Medicines led gains among biopharma ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00241","IE00BZ08YS42.EUR","01093","XLV","IE00BPRC5H50.USD","600276","86618","LU0405327494.USD","BK1189","LU1008478684.HKD","LU1255011170.USD","BK1583","BK1502","BK4137","BK0196","AIPO","BK0216","BK1571","LU0456827905.SGD","09637","BK4585","688180","LU1226287529.USD","BK0028","01877","06618","02315","LABU","ONC","CHAT","LU0315179316.USD","LU1808992512.USD","01801","BK1161","BK0012","LU2328871848.SGD","BK0239","LU1807302812.USD","LU1251922891.USD","BK1191","XBI","603259","LU1303224171.USD","ARTY","LU2039709279.SGD","LU0140636845.USD","AGIX","HCSG","ISBC","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146061353","title":"Junshi Bio appoints Chen Liang as Independent Non-Executive Director; committee leadership realigned","url":"https://stock-news.laohu8.com/highlight/detail?id=1146061353","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146061353?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:44","pubTimestamp":1782481477,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that shareholders approved the election of Chen Liang as an Independent Non-Executive Director at the annual general meeting on 26 June...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173053017","title":"JUNSHI BIO Appoints Chen Liang as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1173053017","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173053017?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:12","pubTimestamp":1782479544,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (ASX: 01877) has announced that the resolution regarding the election of Mr. Chen Liang as an independent non-executive director was approved at the Annual General Meeting held on June 26,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1583","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.0546},{"period":"1month","weight":0.2049},{"period":"3month","weight":-0.3058},{"period":"6month","weight":-0.1635},{"period":"1year","weight":-0.3216},{"period":"ytd","weight":-0.1321}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.1164},{"period":"3month","weight":-0.0307},{"period":"6month","weight":-0.095},{"period":"1year","weight":-0.0098},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.021039},{"month":6,"riseRate":0.375,"avgChangeRate":-0.04216},{"month":7,"riseRate":0.625,"avgChangeRate":0.001275},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"JUNSHI BIO","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"JUNSHI BIO,01877,JUNSHI BIO股票,JUNSHI BIO股票老虎,JUNSHI BIO股票老虎国际,JUNSHI BIO行情,JUNSHI BIO股票行情,JUNSHI BIO股价,JUNSHI BIO股市,JUNSHI BIO股票价格,JUNSHI BIO股票交易,JUNSHI BIO股票购买,JUNSHI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}